中新经纬9月4日电 (林琬斯)近日,分别被称为港股与A股“重组胶原蛋白第一股”的巨子生物、锦波生物相继交出2025年上半年成绩单:巨子生物在营、利规模上远超锦波生物,但增长幅度不及后者。重组胶原蛋白赛道被称为企业的“财富密码”。不过今年上半年,巨子生物与锦波生物的毛利率均有不同程度的下滑。巨子生物营收是锦波生物3倍多近日,巨子生物控股有限公司(下称巨子生物)披露半年报称,今年上半年,公司实现营业...
Source Link中新经纬9月4日电 (林琬斯)近日,分别被称为港股与A股“重组胶原蛋白第一股”的巨子生物、锦波生物相继交出2025年上半年成绩单:巨子生物在营、利规模上远超锦波生物,但增长幅度不及后者。重组胶原蛋白赛道被称为企业的“财富密码”。不过今年上半年,巨子生物与锦波生物的毛利率均有不同程度的下滑。巨子生物营收是锦波生物3倍多近日,巨子生物控股有限公司(下称巨子生物)披露半年报称,今年上半年,公司实现营业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.